For the right patient, an Implantable Contact Lens — or ICL — is one of the most elegant refractive surgery options available. It corrects very high prescriptions that LASIK cannot safely treat. It preserves the natural structure of the cornea. And the result is rapid, stable, and removable.
ICLs are not for everyone. But for patients who are not LASIK candidates, they are often the answer.
What an ICL is
An ICL is a soft, flexible lens implanted inside the eye between the iris (the colored part) and the natural lens. It is not on the cornea (like a contact lens), nor does it replace the natural lens (like a cataract IOL). It sits inside the eye, behind the iris, in front of the natural lens — quietly correcting refractive error for as long as it remains there.
The current generation in the United States is the EVO ICL, manufactured by STAAR Surgical. It is biocompatible (the material has been used in eye surgery for decades), provides UV protection, and includes a central port that improves fluid flow inside the eye, eliminating the need for a separate iridotomy procedure that older ICL designs required.
Who is a good candidate
- Adults 21-45 with a stable prescription
- High myopia (typically -3 to -20 diopters; sweet spot is -6 to -15)
- Some hyperopia (less commonly used for farsightedness)
- Astigmatism up to about 4 diopters (with the toric ICL)
- Adequate space inside the eye (anterior chamber depth)
- Healthy corneas — particularly thin corneas that rule out LASIK
- No cataract development yet
- Realistic expectations
Who is not a good candidate
- Patients with shallow anterior chamber depth (<2.8 mm) — risk of crowding
- Active uveitis or other inflammatory eye conditions
- Glaucoma or pre-glaucoma with concerning angle anatomy
- Significant cataracts — these patients are usually better served by lens replacement (cataract surgery with premium IOL or refractive lens exchange)
- Endothelial cell counts below safe thresholds
- Patients over 45 typically benefit more from refractive lens exchange than ICL because cataract development is approaching anyway
Pre-operative workup
The evaluation is more comprehensive than for LASIK because the surgeon needs detailed inside-the-eye measurements:
- Standard refraction and visual acuity
- Corneal topography
- Anterior chamber depth measurement (by Pentacam, Scheimpflug imaging)
- White-to-white corneal diameter (for sizing)
- Endothelial cell count (specular microscopy)
- Detailed examination of the angle (gonioscopy)
- Pupil size measurement
- Dilated retinal exam
The procedure
ICL surgery is outpatient. Anesthetic eye drops and mild oral sedation keep the patient comfortable. Two small incisions are made at the edge of the cornea. The folded lens is inserted through one incision and gently unfolded inside the eye, where it tucks behind the iris. The procedure takes 15-20 minutes per eye.
The second eye is typically operated on a few days to a week after the first.
Recovery
Most patients have functional vision within 24 hours. Day-after vision is usually clearer than the patient has had since childhood for those with high prescriptions. Antibiotic and anti-inflammatory drops are used for several weeks. Follow-up appointments are at 1 day, 1 week, 1 month, 3 months, and 6 months post-op.
Activity restrictions are minimal. No swimming or heavy contact sports for 2 weeks. Vision continues to refine for 3-6 months as the eye fully accommodates to the new optical system.
What patients describe
Two common observations:
First, the visual quality is striking. Because the corneal optics are not altered, ICL patients often experience excellent contrast sensitivity and night vision compared to LASIK — particularly important for patients who had high pre-op prescriptions.
Second, the recovery is fast. Vision improvement happens overnight rather than over weeks.
Risks and considerations
ICL is a high-success-rate procedure but is intraocular surgery and carries the risks any eye-entering procedure carries — inflammation, infection (rare), pressure spikes (manageable), and rare complications related to lens position. Long-term endothelial cell loss is a consideration for patients with marginal endothelial counts; routine monitoring is important.
The ICL can be removed or exchanged if needed. Most patients keep their ICLs for life, but the option remains available — particularly relevant if a patient eventually develops cataracts and needs cataract surgery.
Cost and insurance
Like most refractive surgery, ICL is generally not covered by insurance. Cost typically ranges from $4,000-$5,500 per eye, somewhat higher than LASIK. HSA and FSA accounts can be used.
How ICL fits in the broader refractive landscape
For most patients with mild to moderate refractive error, LASIK or PRK remains first-line because corneal procedures are safe, fast, and well-established. For patients ruled out by thin corneas, very high prescriptions, or specific contraindications, ICL is often the right next consideration. For patients over 45, refractive lens exchange may be a better choice because it addresses both refractive error and emerging presbyopia.
For more on the full range of refractive options, see the LASIK and Refractive Surgery page.
